BIIB vs DBVT Valuation Comparison 2026 — Intrinsic Value Analysis

Quick Summary — BIIB scores higher on quality with 8.4/10 vs DBVT's 4.9/10. BIIB trades at $188.83 while DBVT trades at $18.23. Both analyzed daily using SEC EDGAR data across 13 institutional models.

BIIB

Biological Products, (No Diagnostic Substances)

Biogen Inc.

Quality

8.4

out of 10

Value Trap

23

SAFE

Price

$188.83

Last close

Models

13/13

Active

VS

DBVT

Biological Products, (No Diagnostic Substances)

DBV Technologies S.A.

Quality

4.9

out of 10

Value Trap

32

LOW

Price

$18.23

Last close

Models

8/13

Active

BIIB

Quality Score 8.4/10 — top tier

Limited to 2/13 visible models

DBVT

2 models active

Quality 4.9/10 — below average

BIIB vs DBVT — Fair Value Comparison

BIIB

DBVT

Market Price Model 1 Model 2

Model-by-Model Comparison

Model	Type	BIIB Fair Value	BIIB Upside	DBVT Fair Value	DBVT Upside
Bayesian DCF	Intrinsic	$136.51	-27.7%	$6.85	-62.4%
Earnings Power Value	Intrinsic	$103.55	-45.2%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$22.88	-87.9%	$6.78	-62.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

BIIB vs DBVT — Which Stock Is More Undervalued in 2026?

BIIB scores higher with a 8.4/10 quality rating vs DBVT's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do BIIB and DBVT Valuations Compare?

At $188.83, BIIB trades +27.7% above its Bayesian DCF fair value of $136.51, while DBVT at $18.23 trades +62.4% above its estimate of $6.85. DBVT shows a wider gap between price and intrinsic value.

Quality of Company: BIIB vs DBVT

BIIB earns a Quality of Company score of 8.4/10 compared to DBVT's 4.9/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: BIIB vs DBVT

BIIB carries a SAFE value trap risk (23/100) while DBVT shows LOW risk (32/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.

Both in Biological Products, (No Diagnostic Substances)

Both BIIB and DBVT operate in Biological Products, (No Diagnostic Substances), which has 6 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare BIIB vs DBVT differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

BIIB

View Full Biogen Inc. Analysis →

DBVT

View Full DBV Technologies S.A. Analysis →